TY - JOUR T1 - Initial Safety and Outcomes of Miriplatin plus Low-dose Epirubicin for Transarterial Chemoembolisation of Hepatocellular Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 5039 LP - 5044 VL - 32 IS - 11 AU - JIN IWAZAWA AU - NAOKO HASHIMOTO AU - SHOICHI OHUE AU - TAKASHI MITANI Y1 - 2012/11/01 UR - http://ar.iiarjournals.org/content/32/11/5039.abstract N2 - Aim: To evaluate the initial safety and efficacy of combination therapy using miriplatin plus low-dose epirubicin for transarterial chemoembolisation (TACE) of unresectable hepatocellular carcinoma (HCC). Patients and Methods: Patients who underwent TACE using miriplatin plus epirubicin (n=48) and control patients who underwent TACE using miriplatin-alone (n=51) were included in this study. Results: The objective response rate in the miriplatin plus epirubicin group (91%) was significantly higher than that in the miriplatin group (74%, p=0.024). Concomitant use of miriplatin and epirubicin was an independent factor associated with higher objective response rate (hazard ratio=0.18; p=0.012). Overall incidence adverse events was not significantly different between the miriplatin plus epirubicin group (50%) and the miriplatin group (49%, p=0.575). Conclusion: TACE using miriplatin plus low-dose epirubicin was associated with an increased objective response rate and comparable adverse effects compared to TACE using miriplatin-alone. ER -